This new Pixel 9 rival offers a 7,000mAh battery, 120W charging, and a fully-cooled back
TL;DR Realme has announced the realme GT7 and GT7 Dream Edition phones.
Both phones feature a 7,000mAh battery paired with 120W wired charging.
The Dream Edition device is effectively an Aston Martin F1-themed smartphone.
Realme has long had a reputation for offering well-priced Android phones, but the company has also pushed battery technology in the last year. The realme GT7 Pro delivered a 6,500mAh battery, and the newly announced realme GT7 ups the ante even more.
The company just launched the realme GT7, and it offers a 7,000mAh battery in concert with 120W wired charging. The manufacturer claims this combination is a first for the industry. In any event, the company says you can expect a 1% to 100% charge in 40 minutes. You'll presumably need to add a few minutes if you're going from dead to full. Realme's phone also supports bypass charging, which directly powers the phone instead of charging the battery. Unfortunately, there's no wireless charging support here.
Nevertheless, this 7,000mAh battery is almost double the capacity of the Galaxy S25 Edge (3,900mAh) and significantly larger than the Galaxy S25 Ultra's 5,000mAh pack.
Does the realme GT7 bring the (figurative) heat?
The GT7 also debuts the Dimensity 9400e processor, which is effectively last year's MediaTek Dimensity 9300 Plus chipset. So the device should offer great performance on par with last year's flagship Android phones. The phone also packs a 6.78-inch 120Hz OLED screen (2,780 x 1,264, 6,000 nits peak brightness, 2,160Hz PWM dimming).
Realme's latest phone also sports a relatively flexible rear camera system. It consists of a 50MP IMX906 main camera, a 50MP 2x telephoto camera (Samsung JN5), and an 8MP ultrawide lens. A 32MP camera is available for selfies and video calls. As for camera features, you can expect Lightning Snap functionality for fast-moving subjects, a 4K/60fps underwater mode, 4K/120fps slow-motion video, and three styles for 'travel' photography (mountain, island, and city). The phone also offers an interesting AI Landscape Plus feature. This reduces haziness and fogginess when taking photos of landscapes while also correcting skewed composition.
Staying with software features, realme is also offering an AI Planner feature. You need to double-tap the phone's back panel to summon this feature, which then scans on-screen content (e.g. times and locations) and automatically generates events in your schedule. One example cited by realme was using this in a WhatsApp chat to plan a night out, with the AI Planner able to accurately capture the time and date. The feature can also be used when viewing notifications or images like event posters, as well as in your booking/accommodation emails.
As for durability, the realme GT7 offers an IP69 rating and Gorilla Glass 7i on the front. Realme also made a big deal out of the graphene layer found underneath the phone's rear cover, claiming this offers a six-fold improvement in thermal conductivity compared to glass covers alone. The company also claims this should result in a phone that feels cool in summer and 'warm and gentle' in winter.
realme GT7: Pricing and availability
Rita El Khoury / Android Authority
Realme also announced the GT7 Dream Edition, which is effectively the GT7 Aston Martin F1 Edition. This phone features a distinctive design, including a bold green color scheme that's a refreshing departure from other manufacturers' green colorways. In fact, colleague Rita El-Khoury reckons this is the most beautiful color she's ever seen on a smartphone. Of course, the Aston Martin logo appears on the back, too. The special edition device also comes with an F1 car SIM ejector tool, a special phone case, and customized software. The latter includes a special wallpaper, green-hued icons, and an exclusive camera watermark.
You can expect to pay a starting price of €749.99 (~$852) for the 12GB/256GB realme GT7, all the way up to €899.99 (~$1,022) for the 16GB/512GB option. Want the realme GT7 Dream Edition? Then you'll be paying €899.99 (~$1,022) for the sole 16GB/512GB variant.
In any event, the phone compares favorably to the €899 Pixel 9. You do miss out on wireless charging, but you gain
Got a tip? Talk to us! Email our staff at
Email our staff at news@androidauthority.com . You can stay anonymous or get credit for the info, it's your choice.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
This CEO explains how the trade war upends global supply chains
Tariff uncertainty has companies doubling down on supply chains. Eric Clark, CEO and president of supply-chain technology provider Manhattan Associates (MANH), joins Market Catalysts to discuss how companies are leaning into supply chain technology to navigate uncertainty and maintain strategic operations. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts here. Supply chain technology provider Manhattan Associates reporting second quarter results earlier this week boosted by demand for its cloud services. Joining me now is Eric Clark, Manhattan Associate CEO and president. Good to see you, Eric. Thank you for joining us. Before I sort of dive into your numbers, I do want to talk about tariffs and the trade war because obviously, your clients are sitting at the intersection of all of those cross currents. What are you hearing from clients right now as to sort of how they're navigating the tariffs? Yeah. Well, first of all, thanks for having me. And what we're seeing is early days when these tariffs were announced right after Liberation day, lots of customers maybe went into a little bit of a pause mode to try to predict what was going to happen or to try to understand the uncertainty. Since then, I think people have understood that this isn't going to be quick, and some of these deadlines are going to move. And it's going to take some time. So the forward leaning companies are really getting back to their strategies and executing their strategies. And I think it's not too dissimilar to what we've seen with other supply chain disruptions like COVID and bridge collapses, et cetera. While there's a little bit of a pause in the beginning, I think it very quickly confirms the fact that supply chain is mission critical software. And this is not an area that companies are going to pause or delay for a long time. This is an area that they consider not only mission critical, but strategic. At the beginning of the year, we were also seeing not just some contracts being paused, but the opposite in some cases, right? Orders coming in to try to sort of front run the tariffs to build up inventory. Is that inventory now? Has it been worked down? Are we how, in other words, I guess right now, how would flows compare to normal conditions? Yeah, it varies across industry, and, you know, what we're seeing from our customers is they're trying to be prepared for whatever might come next. And from a software perspective, that's what we do. You know, we can help them be prepared and make sure that they can react and have their correct strategies and agility so that they can do the things that they need to do in real time. And so when it comes to your business, I know that a lot of the contracts that you all sign are sort of longer term contracts, right? Have you seen any disruption to that? Have you seen any of your customers sort of pulling back on spending amidst all of this? You know, it's interesting, as you mentioned, we announced earnings earlier this week, and we had a strong Q2 and a strong first half. It was a beaten raised quarter, and with really strong margin expansion. And when you look at, you know, the difficult and uncertain macroeconomic environment, the past three quarters at Manhattan have been our strongest bookings, sales quarters in the history of the company. So you can argue that all three of those quarters were, if not challenging, at least changing macro environment, and we continue to do well from a bookings performance. And not only that, but new logo bookings has been the strength of our bookings performance. So we're able to actually go out there and take market share from our competitors. And you know, that also gives us opportunity to continue to expand and cross-sell into those customers in the future. So we're feeling really good about the commitments that our customers are making and that customers in the supply chain space are making with their supply chain software. And Eric, would you say I think sort of during the pandemic, we all paid a lot more attention to supply chains than we ever had, of course, because they were affecting us directly. But there was also a lot of discussion about how antiquated the systems were, both the actual physical infrastructure, but also sort of the things that you help people do now, right? That that stuff was sort of obsolete in many cases. Where are we now? And how much further does supply chain modernization need to go? Well, I think we're in the early days of supply chain modernization. And at Manhattan, I think we're rated a leader across our product portfolio, and I think we're really the only true cloud-based SAS provider across the supply chain space. And that's why we continue to have high win rates in the market, and that's why we continue to drive that expansion with these strong bookings quarters. Again, I point to with this uncertainty in the market, it is confirming the fact that this is mission critical software and confirming the fact that this needs to be part of the strategy. And that's why people are really leaning into the modern technology that we can offer. Eric, thanks so much for joining us. Appreciate it. Yeah, thank you. Related Videos BlackRock's Rick Rieder: I Think Rates Can Come Down Elon Musk's 'master plan': Is Tesla an EV maker or AI play? How meme stock mania is a 'sign of the times' 'We ask for more data' than FICO: VantageScore CEO Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Fox News
9 minutes ago
- Fox News
Expert touts Trump's AI push: 'Best step this country could have taken'
Rhombus Power Inc. founder and CEO Anshuman Roy joins 'Fox News Live' to weigh in the U.S. push to accelerate AI development.
Yahoo
36 minutes ago
- Yahoo
Pharma sector outlook as Trump's drug tariff deadline looms
Pharmaceutical stocks are in focus as President Trump's drug tariff deadline looms. Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination with Josh Lipton to discuss the impact that pharmaceutical tariffs could have on the sector, Astrazeneca's (AZN) $50 billion commitment to US investments, and how the industry is navigating pressure from Washington and shifting global demand. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. Pharmaceutical stocks in focus as we approach President Trump's looming drug tariff deadline. For more, I want to bring in Yahoo Finance senior health reporter Angelique Chenge. That's right, Josh. With that looming deadline, potentially August 1st, for up to 200% in tariffs, we don't know what that number will actually end up being. We've heard from several companies that have announced manufacturing commitments in hopes to thwart that effort. That includes AstraZeneca. We spoke to CEO Pascal Soriot about that, and he did mention that the announcement for $50 billion, that's in addition to $3.5 billion last year, is in part a response to Trump's tariffs. We know others like Eli Lilly and Johnson & Johnson have also announced similarly big announcements of commitments for manufacturing. And this is in play at a time where the industry is also going through a bit of tumult. We know that there is a lot of investment in one of Trump's least favorite countries, that is China. That is the reason why there has been a lot of tension in the biotech world. We also know that big pharma has been pivoting and investing there as well. Licensing deals and the like are on the rise as they look to sort of respond to all the different countries that are looking for what has now been termed health sovereignty. And this plays into that. So, when I asked Pascal about that, about China and the deal making there, here's what he had to say about it. We believe that it's our ethical responsibility to bring medicines to as many people as possible. Of course, there are limitations to what we can do, but we work very hard to do this. And we are lucky enough or good enough or both, that we are growing. And growth brings opportunities. And because we are growing, we are able to invest in United States for the United States, we're able to invest in China for China, and we're also able to seek innovation where it happens. Because actually, if innovation happens in China or in Europe, we need to take this innovation, develop it, and bring it to patients for instance in the United States, but manufacture the product in the United States. Um, and I think that brings me to an important point that people don't talk enough about is that today innovation in our industry takes place in the U.S. U.S. is the biggest innovator for biopharmaceuticals. And it's really important that everything is done to protect that innovation. It's a fantastic engine to bring new medicines to patients but also create good jobs, well-paid jobs, and economic growth. So, as you can hear, a lot of focus on that, on economic growth being the driver as well and needing to respond to these countries and their efforts. AstraZeneca also talked about how it would help shift revenues for the portfolio with a greater reliance on the U.S. Currently, 42% of revenues comes from the U.S. And with this increase in manufacturing, it would be 50%. And that includes GLP-1s. We know that there's a lot of global demand for that drug and for those types of drugs. AstraZeneca has been pursuing an oral form or pill form, which is largely seen as the next frontier in this space. AstraZeneca looking at being able to then supply the rest of the world from the U.S., making it a larger exporter. So, here's what Pascal said about that. It's also a reason, another reason why we are investing in this very large facility. We have our oral GLP-1. Everybody knows GLP-1 by now. These are agents used to help people manage their weight. We have an oral agent, and we have bet on oral agents because we think they are going to be easier for patients, because they will be cheaper, they'll be more accessible, and we will be able to export them around the world, not only supply America. But we also have other products treating cardiovascular metabolic disease. We have a new agent for hypertension for patients who are not controlled on multi-medicines. We have an oral PCSK9 for the control of cholesterol and many others. Cardiovascular metabolic diseases are the biggest killer in the world today, including in the United States. So, you can see the needs are enormous. This plant will supply products for American patients, so American patients will access products that are American-made. But this plant will also export to the billions of patients around the world who need these medicines. The company really moving that pot of money, you know, globally and looking at where it makes the most sense. Pascal also did tell me that in looking at the different areas of the world where the money can be, you know, invested, China, of course, being one of them. And then if you compare the amount that has been put in there, that is $5.3 billion is one of the latest deals that AstraZeneca has done in China. And if you compare that to the $50 billion, while not on the same level, you can still see it's quite a large number. And that's just one of those deals. So, we're starting to see a little bit of bifurcation in how the global pharmaceutical economy is functioning. Related Videos Uncertainty is 'here to stay': What that means for markets BlackRock's Rick Rieder: I Think Rates Can Come Down Elon Musk's 'master plan': Is Tesla an EV maker or AI play? 'We ask for more data' than FICO: VantageScore CEO Sign in to access your portfolio
